Quarter | Prior | Estimate | Actual | Surprise | |
---|---|---|---|---|---|
Q4 2021 Pre-Market | EPS: REV: | 0.74 4.176B | |||
Q3 2021 Pre-Market | EPS: REV: | 0.48 2.448B | |||
Q2 2021 Pre-Market | EPS: REV: | ||||
Q1 2021 Pre-Market | EPS: REV: | 0.62 2.617B | |||
Q4 2020 Pre-Market | EPS: REV: | 0.63 2.606B | 0.71 4.11B | 0.74 4.176B | 4.23% 1.61% |
Q3 2020 Pre-Market | EPS: REV: | 0.74 2.711B | 0.46 2.43B | 0.51 2.448B | 10.87% 0.74% |
Q2 2020 Pre-Market | EPS: REV: | 0.66 2.681B | 0.52 2.47B | 0.54 2.45B | 3.85% -0.81% |
Q1 2020 Pre-Market | EPS: REV: | 0.69 2.723B | 0.62 2.61B | 0.62 2.617B | 0% 0.27% |
Q4 2019 Pre-Market | EPS: REV: | 0.65 2.669B | 0.63 2.59B | 0.62 2.606B | -1.59% 0.62% |
Q3 2019 Pre-Market | EPS: REV: | 0.65 2.579B | 0.65 2.65B | 0.74 2.711B | 13.85% 2.3% |
Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!
News Coverage
- Mid-Day Market Update: IBM Drops On Downbeat Revenue; Montauk Renewables Shares Surge
- Coronavirus Challenges CSX's Fourth Quarter
- Kansas City Southern's Q4 Net Income Rises 30%
- Why IBM And Intel Are Trading Lower Today
- Return On Capital Employed Overview: Sirius XM Holdings
- ROCE Insights For Walmart
- ROCE Insights For Visa
- Looking Into Biocryst Pharmaceuticals's Return On Capital Employed
- Return On Capital Employed Overview: Aemetis
- Looking Into Fluidigm's Return On Capital Employed